• Moderator: Jean Sullivan, RN, MA
• Kathleen Russell, JD, MN, RN
  National Council of State Boards of Nursing (NCSBN)
  Chicago, Illinois
   
• Presentation Handout

Objectives:

1. Compare and contrast the different types of ATD programs in the following areas: relationship to the disciplining authority, funding of operational costs, number of participants monitored staffing ratio and number of disciplines monitored.
2. Critique the length of monitoring agreements.
3. Evaluate medication administration clauses in monitoring agreements.
4. Identify operational policies and procedures staff currently views as best practices. Discuss current legal challenges programs are encountering.
   

We would like to build on what we learned last year so here are some questions to guide our discussion. Please feel free to discuss those you find most interesting. We hope everybody will have something to say about each topic. Also, please feel free to add additional questions you think are important.

Please review/answer the questions below in advance of the conference. When complete, please email them to the NOAP Executive Office. Your answers will be discussed during the workshop. 

1. What is your relationship with the disciplining authority; free standing, part of the board, contract, and any other relationship might have.
2. How many disciplines do you monitor?
3. How long are your practice agreements, 2, 3, 5 years or more?
4. Do you have facilitated peer support groups?
5. What are the credentials of the facilitators?
   1. Do you use teleconference groups?
   2. What is the average frequency of drug screening?
6. Do you use a variety of panels and hair and nail?
7. What is your feeling about Observed Collections?
8. What is your policy on medication assisted treatment?
9. Do you allow nurses to return to practice on suboxone or other opioid substitute?
10. What were your challenges?
11. From a regulatory/program standpoint, what would you like to change?
12. Identify 2 things you are striving to achieve.
13. What percentage of the nursing population are in the Program?
14. Does your ATD program have an Advisory Committee? If so, what is the composition of the Committee? How often does the Committee meet?
15. Does your ATD program test for any of the following substances: Promethazine, Diphenhydramine, and Cyclobenzaprine?
16. Does your ATD program have a matrix with criteria for determining the length of the participant’s enrollment in ATD?
17. Do all of your ATD participants automatically place their licensure on an inactive status upon enrollment?
18. Do you have any practice areas that are strictly prohibited for ATD participants to work in? When an ATD participant returns to work, is the practice setting considered on a case-by-case setting?
19. Does your ATD program collect and aggregate data for your Board? If so, what data elements are collected?
20. Does your General Counsel or Executive Director sign off on every ATD contract that is presented to a potential participant?
21. Does your ATD contract/agreement require that the nurse/participant make all of their nursing licenses inactive or just the state in which they are entering the ATD program?
22. Does your ATD program notify other states in which the participant holds licensure of their participation in an ATD program (i.e. Speed Memo or other correspondence)?  
    

• Scott A. Teitelbaum, MD, FAAP, DFASAM
  University of Florida, College of Medicine
  Gainesville, Florida
   
• Presentation Handout

Objectives:

1. Name three direct biomarkers of alcohol consumption.
2. Describe the temporal windows of detection for alcohol and its direct biomarkers.
3. Identify the sources of clinical false positive and clinical false negative results in alcohol biomarker testing.
4. Identify the most commonly observed direct alcohol biomarker in participants and new evaluees in Florida’s professionals health programs.

• Bari Platter, MS, RN, PMHCNS-BC
  CeDAR- Center for Dependency, Addiction and Rehabilitation at University of Colorado Hospital
  Denver, Colorado
   
• Presentation Handout

Objectives:

1. Understand how cannabis affects the brain.
2. Review the effects of cannabis use.
3. Describe current treatment approaches in working with clients with problematic cannabis use and CUD.
4. Discuss considerations for safe practice, particularly in States that have legalized medical and/or recreational cannabis.

• Dana Murphy-Parker, MS, CRNP, PMHNP-BC, CARN-AP
  Widener University
  Philadelphia, Pennsylvania
   
• Presentation Handout

Objectives:

1. Discuss the history of addiction in the USA and how the history impacts stigma, misunderstanding and the lack of addiction education in our profession and our society today.
2. Review the past, present and future of the International Nurses Society on Addiction.
3. Define the role of IntNSA and IntNSA’s work focused on the opioid epidemic.
4. Perform a wrap up of the presentation.

• Barbara McGill, MSN, RN
  Baton Rouge, Louisiana
   
• Presentation Handout

Objectives:

1. List at least one new trend in Alternative Programs.
2. Define Hostile Work Environment legally speaking.
3. Discuss Injectable Suboxone and other Medication Assisted Treatments.

• Linda L. Smith, RN, M.Div, CAP, CARN-AP
  Intervention Project for Nurses
  Jacksonville, Florida
   
• Shannon O. Large, DNP, APRN, ANP-BC, CARN-AP
  Intervention Project for Nurses
  Jacksonville, Florida
   
• Presentation Handout; Audio

Objectives:

1. Recognize the difference between boundary crossing, boundary violation and sexual misconduct.
2. Describe how Fl IPN manages cases with boundary issues vs. sexual misconduct.
3. Acknowledge the importance of maintaining healthy boundaries with clients.

Sunset Cruise

Click here for more information, max capacity is 40 passengers.

Click here to purchase tickets.

• Gregory Gable, Psy.D
  Caron Health Care Professional Programs
  Wernersville, Pennsylvania
   
• Presentation Handout

Objectives:

1. The participant will be able to define and discuss the concept of cognitive reserve and how it impacts the process of cognitive assessment of high-functioning individuals such as health professionals.
2. The participant will be able to understand and discuss the use of modified normative data in the process of neurocognitive assessment of health professionals.

• Moderator: Kathie Simpson, RN, BSN, CACPN
• James Ferguson, DO, DFASAM, C-MRO; FSSolutions; Chalfont, Pennsylvania
• Joe Jones, PhD, USDTL; Des Plaines, Illinois
• Barry Lubin, MD, FASAM, MRO; Affinity Online Solutions; Vienna, Virginia
• Donna Smith, PhD, EdD; RecoveryTrek; Virginia Beach, Virginia
• Deb Motika, DRUGSCAN, Inc
   
• In order to best serve your needs please submit a question or a brief case study regarding drug screening to monitor abstinence using the CASE STUDY TEMPLATE.
   
• Presentation Handout

Objectives:

1. Discuss the pros and cons of PEth vs blood spot.
2. Describe the limitations of hair testing and understand how that impacts the interpretation of their program results.
3. Describe the anatomy of a fingernail and how drug is incorporated into fingernail.
4. Relate case study reports from the literature and our laboratory experience to better interpret their cases at their program.

• Agenda, including Membership and Finance Report
• Membership List
  
• 2018 Business Meeting Minutes

• Robert L. DuPont, MD
  Institute for Behavior and Health
  Rockville, Maryland
   
• Presentation Handout

Objectives:

1. Identify the consequences of the mismatch of brief episodes of treatment and the life-long nature of substance use disorders.
2. Describe the essential elements and outcomes of physician health program (PHPs).
3. Articulate the widespread applications of the PHP model as part of the New Paradigm for long-term recovery.

• James Stoltz, MHS, CRNA, CARN
  Clarksville, Tennessee
   
• Julie Rice, BA
  AANA Health & Wellness and Peer Assistance Programs
  Park Ridge, Illinois
   
• Presentation Handout

Objectives:

1. Identify the benefits of a comprehensive evaluation and addiction treatment plan with considerations specific to an anesthesia professional’s drug access and addressing mental health co-morbidities.
2. Assess reasons five-year monitoring is recommended for certified registered nurse anesthetists.
3. Explain the value of communication and collaboration between the treatment program and the monitoring program.
4. Compare return to work considerations between health care professionals with and without access to potent anesthesia drugs.

• Sharon Theroux, PhD, ABPP
  Licensed Psychologist, Founder, South Florida Center for Mindfulness Co-Founder, International Seminars Group
  Boca Raton, Florida
   
• Presentation Handout

Objectives:

1. Define Mindfulness.
2. Practice an awareness of breathing meditation.
3. Review the effectiveness of mindfulness-based interventions for people with depression and addictive behaviors.